
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's strong cash position of approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables at the end of Q3 2025 highlights its financial stability and potential for continued investment in research and development. Additionally, positive developments in the ongoing Phase 3 DYNASTY-Breast02 trial for BNT323 and the promising immune responses generated by their LP.8.1-adapted monovalent COVID-19 vaccine underscore BioNTech's innovative capabilities in both oncology and infectious disease markets. These factors contribute to a favorable outlook for the company's growth prospects and long-term success in the biotechnology sector.
Bears say
The negative outlook on BioNTech's stock is driven by multiple risks, including the potential for negative clinical data from several pipeline programs, slower-than-expected market uptake of its therapies, and regulatory uncertainties which could hinder commercial success. Additionally, the company reported a net loss per diluted share of €0.12 for the third quarter of 2025 and is projected to have a full-year net loss per diluted share of €3.99, indicating ongoing financial challenges. Moreover, the heightened volatility in the COVID-19 vaccine market and a more restrictive regulatory environment in the U.S. may distract investors from BioNTech’s long-term oncology initiatives.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares